Photochemical treatment of plasma with amotosalen and long-wavelength ultraviolet light inactivates pathogens while retaining coagulation function

Transfusion

Volumn 46, Issue 7, 2006, Pages 1168-1177

  Singh, Yasmin ^a   Sawyer, Lynette S ^a   Pinkoski, Linda S ^a   Dupuis, Kent W ^a   Hsu, Jocelyn C ^a   Lin, Lily ^a   Corash, Laurence ^a  

^a CERUS CORPORATION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA 2 ANTIPLASMIN; AMOTOSALEN; ANTITHROMBIN; BLOOD CLOTTING FACTOR 10; BLOOD CLOTTING FACTOR 11; BLOOD CLOTTING FACTOR 13; BLOOD CLOTTING FACTOR 5; BLOOD CLOTTING FACTOR 7; BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING FACTOR 9; FIBRINOGEN; FRESH FROZEN PLASMA; PROTEIN C; PROTEIN S; PROTHROMBIN; THROMBOCYTE CONCENTRATE;

ARTICLE; BABESIA MICROTI; BLOOD CLOTTING; BLUETONGUE ORBIVIRUS; BORRELIA BURGDORFERI; BOVINE DIARRHEA VIRUS; DISINFECTION; HEPATITIS B VIRUS; HEPATITIS C VIRUS; HUMAN; HUMAN ADENOVIRUS 5; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN T CELL LEUKEMIA VIRUS 1; HUMAN T CELL LEUKEMIA VIRUS 2; HUMAN TISSUE; KLEBSIELLA PNEUMONIAE; PHOTOCHEMISTRY; PLASMA; PLASMA TRANSFUSION; PLASMODIUM FALCIPARUM; SARS CORONAVIRUS; STAPHYLOCOCCUS EPIDERMIDIS; TREPONEMA PALLIDUM; TRYPANOSOMA CRUZI; ULTRAVIOLET RADIATION; VIRUS INACTIVATION; WEST NILE FLAVIVIRUS; YERSINIA ENTEROCOLITICA;

ANIMALS; BACTERIA; BLOOD COAGULATION; BLOOD COAGULATION FACTORS; BLOOD-BORNE PATHOGENS; DISEASE TRANSMISSION; HUMANS; PARASITES; PHOTOCHEMISTRY; PLASMA; PROTOZOA; PSORALENS; ULTRAVIOLET RAYS; VIRUS INACTIVATION; VIRUSES;

EID: 33746572800     PISSN: 00411132     EISSN: 15372995     Source Type: Journal    
DOI: 10.1111/j.1537-2995.2006.00867.x     Document Type: Article

References (49)

1. Sullivan MT, McCullough J, Schreiber GB, Wallace EL. Blood collection and transfusion in the United States in 1997. Transfusion 2002;42:1253-60.
2. Practice Guidelines for blood component therapy: a report by the American Society of Anesthesiologists Task Force on Blood Component Therapy. Anesthesiology 1996;84:732-47.
3. Dodd RY, Notari EP 4th, Stramer SL. Current prevalence and incidence of infectious disease markers and estimated window-period risk in the American Red Cross blood donor population. Transfusion 2002;42:975-9.
4. Barbara J. Why "safer than ever" may not be safe enough. Transfus Med Hemother 2004;31(Suppl 1):2-10.
5. Phelps R, Robbins K, Liberti T, et al. Window-period human immunodeficiency virus transmission to two recipients by an adolescent blood donor. Transfusion 2004;44:929-33.
6. Fiebig EW, Heldebrant CM, Smith RI, et al. Intermittent low-level viremia in very early primary HIV-1 infection. J Acquir Immune Defic Syndr 2005;39:133-7.
7. Mohr H, Lambrecht B, Knuever-Hopf I. Virus inactivated single-donor fresh plasma preparations. Infusionsther Transfusionsmed 1992;19:79-83.
8. Williamson LM, Cardigan R, Prowse CV. Methylene blue-treated fresh-frozen plasma: what is its contribution to blood safety? Transfusion 2003;43:1322-9.
9. Horowitz B, Bonomo R, Prince AM, et al. Solvent/detergent-treated plasma: a virus-inactivated substitute for fresh frozen plasma. Blood 1992;79:826-31.
10. Horowitz B. Inactivation of viruses found with plasma proteins. Biotechnology 1991;19:417-30.
11. Wagner SJ, Robinette D, Storry I, et al. Differential sensitivities of viruses in red cell suspensions to methylene blue photosensitization. Transfusion 1994;34:521-6.
12. Alford BL. Important new drug warning [monograph on the Internet]. Watertown (MA): V.I. Technologies, Inc. Vitex); 2002. Available from: http://www.fda.gov/medwatch/safety/2002/plassd_deardoc.pdf
13. Osselaer JC, Doyen C, Sonet A, et al. Routine use of platelet components prepared with photochemical treatment (INTERCEPT platelets): impact on clinical outcomes and costs. Blood 2004;104:987a.
14. Wollowitz S. Fundamentals of the psoralen-based Helinx technology for inactivation of infectious pathogens and leukocytes in platelets and plasma. Semin Hematol 2001;38(4 Suppl 11):4-11.
15. Pinna D, Sampson-Johannes A, Clementi M, et al. Amotosalen photochemical inactivation of severe acute respiratory syndrome coronavirus in human platelet concentrates. Transfus Med 2005;15:269-76.
16. Lin L, Hanson CV, Alter HJ, et al. Inactivation of viruses in platelet concentrates by photochemical treatment with amotosalen and long-wavelength ultraviolet light. Transfusion 2005;45:580-90.
17. Jauvin V, Alfonso RD, Guillemain B, et al. In vitro photochemical inactivation of cell-associated human T-cell leukemia virus Type I and II in human platelet concentrates and plasma by use of amotosalen. Transfusion 2005;45:1151-9.
18. Lin L, Dikeman R, Molini B, et al. Photochemical treatment of platelet concentrates with amotosalen and long-wavelength ultraviolet light inactivates a broad spectrum of pathogenic bacteria. Transfusion 2004;44:1496-504.
19. Van Voorhis WC, Barrett LK, Eastman RT, et al. Trypanosoma cruzi inactivation in human platelet concentrates and plasma by a psoralen (amotosalen HCl) and long-wavelength UV. Antimicrob Agents Chemother 2003;47:475-9.
20. Eastman RT, Barrett LK, Dupuis K, et al. Leishmania inactivation in human pheresis platelets by a psoralen (amotosalen HCl) and long-wavelength ultraviolet irradiation. Transfusion 2005;45:1459-63.
21. Grass JA, Hei DJ, Metchette K, et al. Inactivation of leukocytes in platelet concentrates by photochemical treatment with psoralen plus UVA. Blood 1998;91:2180-8.
22. Reed LJ, Muench H. A simple method of estimating fifty-per cent endpoints. Am J Hyg 1938;27:493-7.
23. Heiden M, Seitz R. Quality of therapeutic plasma-requirements for marketing authorization. Thromb Res 2002;107 (Suppl. 1):S47-51.
24. Beeck H, Hellstern P. In vitro characterization of solvent/detergent- treated human plasma and of quarantine fresh frozen plasma. Vox Sang 1998;74(Suppl 1):219-23.
25. Ganem D, Varmus HE. The molecular biology of the hepatitis B viruses. Annu Rev Biochem 1987;56:651-93.
26. Choo QL, Kuo G, Weiner AJ, et al. Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. Science 1989;244:359-62.
27. Abe H, Yamada-Ohnishi Y, Hirayama J, et al. Elimination of both cell-free and cell-associated HIV infectivity in plasma by a filtration/methylene blue photoinactivation system. Transfusion 2000;40:1081-7.
28. Visconti MR, Pennington J, Garner SF, et al. Assessment of removal of human cytomegalovirus from blood components by leukocyte depletion filters using real-time quantitative PCR. Blood 2004;103:1137-9.
29. Pennington J, Taylor GP, Sutherland J, et al. Persistence of HTLV-I in blood components after leukocyte depletion. Blood 2002;100:677-81.
30. Siegl G, Cassinotti P. Presence and significance of parvovirus B19 in blood and blood products. Biologicals 1998;26:89-94.
31. Vrielink H, Reesink HW. Transfusion-transmissible infections. Curr Opin Hematol 1998;5:396-405.
32. Yokozaki S, Toyoda H, Nakano I, et al. Infection with TT virus, a novel transfusion-transmissible DNA virus, in haemophiliacs and in blood products. Br J Haematol 1999;105:1114-9.
33. Hanson CV. Photochemical inactivation of viruses with psoralens: an overview. Blood Cells 1992;18:7-25.
34. Sawyer L, Hanson D, Dupuis K. Inactivation of parvovirus B19 in platelets by Helinx technology. Transfusion 2004;44:102A.
35. McQuiston JH, Childs JE, Chamberland ME, Tabor E. Transmission of tick-borne agents of disease by blood transfusion: a review of known and potential risks in the United States. Transfusion 2000;40:274-84.
36. de Alarcon P, Benjamin R, Dugdale M, et al. Fresh frozen plasma prepared with amotosalen HCl (S-59) photochemical pathogen inactivation: transfusion of patients with congenital coagulation factor deficiencies. Transfusion 2005;45:1362-72.
37. Hambleton J, Wages D, Radu-Radulescu L, et al. Pharmacokinetic study of FFP photochemically treated with amotosalen (S-59) and UV light compared to FFP in healthy volunteers anticoagulated with warfarin. Transfusion 2002;42:1302-7.
38. Mintz P, Neff A, MacKenzie M, et al. Therapeutic plasma exchange (TPE) for thrombotic thrombocytopenic purpura (TTP) using plasma prepared with photochemical treatment (INTERCEPT plasma). Blood 2004;104:239a.
39. Mintz P, Steadman R, Blackall D, et al. Pathogen inactivated fresh frozen plasma prepared using Helinx™ technology is efficacious and well tolerated in treatment of end-stage liver disease patients - the STEPAC trial. Blood 2001;98(Suppl 1):709a.
40. Mintz PD, Avery NL, Moulaison SL, et al. Preparation of cryoprecipitate from photochemically treated fresh frozen plasma. Transfusion 2000;40(Suppl 1):63S.
41. Yarranton H, Lawrie AS, Mackie IJ, et al. Coagulation factor levels in cryosupernatant prepared from plasma treated with amotosalen hydrochloride (S-59) and ultraviolet A light. Transfusion 2005;45:1453-8.
42. Hanson CV, Crawford-Miksza L, Sheppard HW. Application of a rapid microplaque assay for determination of human immunodeficiency virus neutralizing antibody titers. J Clin Microbiol 1990;28:2030-4.
43. Astier-Gin T, Portail JP, Lafond F, Guillemain B. Identification of HTLV-I- or HTLV-II-producing cells by cocultivation with BHK-21 cells stably transfected with a LTR-lacZ gene construct. J Virol Meth 1995;51:19-29.
44. Alter HJ, Creagan RP, Morel PA, et al. Photochemical decontamination of blood components containing hepatitis B and non-A, non-B virus. Lancet 1988;2:1446-50.
45. Feinstone SM, Alter HJ, Dienes HP, et al. Non-A, non-B hepatitis in chimpanzees and marmosets. J Infect Dis 1981;144:588-98.
46. Marion PL, Cullen JM, Azcarraga RR, et al. Experimental transmission of duck hepatitis B virus to Pekin ducks and to domestic geese. Hepatology 1987;7:724-31.
47. Shi PY, Tilgner M, Lo MK, et al. Infectious cDNA clone of the epidemic west nile virus from New York City. J Virol 2002;76:5847-56.
48. Grellier P, Santus R, Mouray E, et al. Photosensitized inactivation of Plasmodium falciparum- and Babesia divergens-infected erythrocytes in whole blood by lipophilic pheophorbide derivatives. Vox Sang 1997;72:211-20.
49. Etkind P, Piesman J, Ruebush TK 2nd, et al. Methods for detecting Babesia microti infection in wild rodents. J Parasitol 1980;66:107-10.